伯舒替尼对新确诊慢性期CML有效

关键信息

该项研究展示了BELA研究中伯舒替尼和伊马替尼治疗新确诊慢性期慢性随性白血病（CML）的随访结果。结果显示，伯舒替尼疗效持久，24个月的累积完全细胞遗传学应答率为79%，累积分子应答率为59%。伯舒替尼治疗相关的副作用可控，常见不良反应主要为胃肠道相关症状和肝功能升高。

作者据此认为伯舒替尼治疗慢性期CML有效，且耐受性可控。

TAKE-HOME MESSAGE

This paper presents follow-up data on the BELA trial that compared bosutinib and imatinib in patients with newly diagnosed chronic-phase CML. Results show promising ongoing efficacy with bosutinib, with cumulative complete cytogenetic response rates by 24 months of 79% and cumulative major molecular response rates of 59%. The toxicities associated with bosutinib continue to be manageable, with the most common being gastrointestinal-related and elevated liver function tests.

The authors conclude that bosutinib demonstrates efficacy and manageable tolerability in this patient population.

British Journal of Haematology

Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukaemia: Results From the 24-Month Follow-Up of the BELA Trial

Br. J. Haematol 2014 Sep 08;[EPub Ahead of Print], TH Brümmendorf, JE Cortes, CA de Souza, F Guilhot, L Duvillié, D Pavlov, K Gogat, AM Countouriotis, C Gambacorti-Passerini

This abstract is available on the publisher's site.

Access this abstract now

Copyright © 2014 Elsevier Inc. All rights reserved.

独家授权，未经许可，请勿转载。